GAL and hepatocellular carcinoma: In addition, galactosylated chitosan was found to be a suitable material for liver-targeting drug/gene delivery or liver tissue engineering [23, 24], and as a hepatocyte-targeting carrier, Gal-CSO nanoparticles have a great promising potential for clinical applications due to their active liver-targeting characteristics and more than satisfactory compatibility with hepatoma cells [8].